Brian Groff

432 total citations
17 papers, 218 citations indexed

About

Brian Groff is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Brian Groff has authored 17 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Brian Groff's work include CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (10 papers) and CRISPR and Genetic Engineering (6 papers). Brian Groff is often cited by papers focused on CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (10 papers) and CRISPR and Genetic Engineering (6 papers). Brian Groff collaborates with scholars based in United States, Norway and Sweden. Brian Groff's co-authors include Bahram Valamehr, Ryan Bjordahl, Bruce Walcheck, Jeffrey S. Miller, Svetlana Gaidarova, Greg Bonello, Sajid Mahmood, Frank Cichocki, Karl‐Johan Malmberg and Tom Lee and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Brian Groff

17 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Groff United States 7 173 147 57 33 12 17 218
Hans De Reu Belgium 9 163 0.9× 186 1.3× 85 1.5× 37 1.1× 8 0.7× 18 261
Sarah A. E. Galloway United Kingdom 3 114 0.7× 158 1.1× 81 1.4× 31 0.9× 9 0.8× 3 237
Gretchen E. Lyons United States 10 191 1.1× 252 1.7× 47 0.8× 65 2.0× 8 0.7× 11 312
Erin Waters United Kingdom 6 66 0.4× 119 0.8× 31 0.5× 25 0.8× 8 0.7× 10 175
Annika M. Bruger Belgium 7 92 0.5× 254 1.7× 75 1.3× 11 0.3× 6 0.5× 9 303
Faustine Lhomme France 9 117 0.7× 96 0.7× 50 0.9× 27 0.8× 16 1.3× 13 201
Lorenz Jahn Netherlands 7 117 0.7× 140 1.0× 68 1.2× 28 0.8× 4 0.3× 15 192
Natalia Izotova United Kingdom 5 140 0.8× 120 0.8× 74 1.3× 57 1.7× 3 0.3× 9 219
Hanna van Ooijen Sweden 4 151 0.9× 233 1.6× 54 0.9× 12 0.4× 4 0.3× 6 301
Judith C. Kaiser United States 4 224 1.3× 267 1.8× 31 0.5× 16 0.5× 14 1.2× 10 306

Countries citing papers authored by Brian Groff

Since Specialization
Citations

This map shows the geographic impact of Brian Groff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Groff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Groff more than expected).

Fields of papers citing papers by Brian Groff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Groff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Groff. The network helps show where Brian Groff may publish in the future.

Co-authorship network of co-authors of Brian Groff

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Groff. A scholar is included among the top collaborators of Brian Groff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Groff. Brian Groff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Hammer, Quirin, Karlo Perica, Rina M. Mbofung, et al.. (2024). Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell. 31(9). 1376–1386.e8. 18 indexed citations
3.
Hammer, Quirin, Karlo Perica, Rina M. Mbofung, et al.. (2022). Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection. Blood. 140(Supplement 1). 1165–1166. 5 indexed citations
4.
Pan, Yijia, Brian Groff, Rina M. Mbofung, et al.. (2022). Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy. Blood. 140(Supplement 1). 4547–4548. 7 indexed citations
5.
Cichocki, Frank, Ryan Bjordahl, Sajid Mahmood, et al.. (2022). Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 140(23). 2451–2462. 58 indexed citations
6.
Mbofung, Rina M., Yijia Pan, Sushil Devkota, et al.. (2022). iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma. Blood. 140(Supplement 1). 7388–7389. 2 indexed citations
7.
Mbofung, Rina M., Yijia Pan, Brian Groff, et al.. (2021). Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection. Blood. 138(Supplement 1). 2795–2795. 2 indexed citations
8.
Pan, Yijia, Brian Groff, Rina M. Mbofung, et al.. (2021). A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy. Blood. 138(Supplement 1). 4800–4800. 1 indexed citations
9.
Goodridge, Jode, Ryan Bjordahl, Sajid Mahmood, et al.. (2021). Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma. Cancer Research. 81(13_Supplement). 1550–1550. 7 indexed citations
10.
11.
12.
Bjordahl, Ryan, Zhu Huang, Paul Rogers, et al.. (2019). Abstract 3191: FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies. Cancer Research. 79(13_Supplement). 3191–3191. 1 indexed citations
13.
Goodridge, Jode, Sajid Mahmood, Zhu Huang, et al.. (2019). FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. Blood. 134(Supplement_1). 301–301. 66 indexed citations
14.
Goodridge, Jode, Sajid Mahmood, Zhu Huang, et al.. (2019). Abstract 3207: Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignancies. Cancer Research. 79(13_Supplement). 3207–3207. 1 indexed citations
15.
Bjordahl, Ryan, Raedun Clarke, Svetlana Gaidarova, et al.. (2017). Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy. Blood. 130. 3187–3187. 1 indexed citations
16.
Kristian, Sascha A., Takayuki Ota, Sarah S. Bubeck, et al.. (2016). Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae. PLoS ONE. 11(5). e0154616–e0154616. 12 indexed citations
17.
Clarke, Raedun, Brian Groff, Tom Tong Lee, et al.. (2016). Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy. Blood. 128(22). 2164–2164. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans De Reu Breakdown of academic impact, for papers by Sarah A. E. Galloway Breakdown of academic impact, for papers by Gretchen E. Lyons Breakdown of academic impact, for papers by Erin Waters Breakdown of academic impact, for papers by Annika M. Bruger Breakdown of academic impact, for papers by Faustine Lhomme Breakdown of academic impact, for papers by Lorenz Jahn Breakdown of academic impact, for papers by Natalia Izotova Breakdown of academic impact, for papers by Hanna van Ooijen Breakdown of academic impact, for papers by Judith C. Kaiser
Rankless by CCL
2026